Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?

Overview Forecast RevenueFinancials Chart

Zentalis Pharmaceuticals Ownership Summary

Zentalis Pharmaceuticals is owned by 72.29% institutional investors, 13.52% insiders, and 14.19% retail investors. Matrix capital management company, lp is the largest institutional shareholder, holding 19.39% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.96% of its assets in Zentalis Pharmaceuticals shares.

ZNTL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Zentalis Pharmaceuticals	72.29%	13.52%	14.19%
Sector	Healthcare Stocks	42.54%	10.83%	46.63%
Industry	Biotech Stocks	45.22%	10.75%	44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Matrix capital management company, lp	13.96M	19.39%	$21.08M
Blackrock	4.82M	6.80%	$19.71M
Vanguard group	2.90M	4.03%	$4.39M
Acadian asset management	2.85M	3.95%	$4.29M
Renaissance	2.33M	3.23%	$3.51M
Tang capital management	1.55M	2.15%	$2.34M
Two sigma advisers, lp	1.46M	2.03%	$2.21M
Morgan stanley	1.41M	1.96%	$2.13M
Two sigma investments, lp	1.36M	1.89%	$2.06M
Decheng capital	1.32M	1.84%	$2.00M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mayo clinic	187.14K	25.27%	$765.41K
Matrix capital management company, lp	13.96M	19.75%	$21.08M
Tybourne capital management (hk)	961.49K	4.69%	$1.45M
Peapod lane capital	565.37K	0.76%	$853.88K
Stonepine capital management	453.80K	0.56%	$685.24K
Decheng capital	1.32M	0.35%	$2.00M
Pfizer	953.83K	0.33%	$1.44M
5am venture management	490.00K	0.27%	$739.90K
Almitas capital	457.32K	0.16%	$690.56K
Gsa capital partners llp	1.08M	0.14%	$1.63M

Top Buyers

Holder	Shares	% Assets	Change
Balyasny asset management	970.86K	0.00%	970.86K
Renaissance	2.33M	0.00%	795.80K
Ubs group	532.68K	0.00%	403.21K
Stonepine capital management	453.80K	0.56%	344.79K
Morgan stanley	1.41M	0.00%	310.18K

Top Sellers

Holder	Shares	% Assets	Change
Eventide asset management	-	-	-4.48M
Opaleye management	316.55K	0.07%	-1.61M
T. rowe price investment management	-	-	-1.33M
Almitas capital	457.32K	0.16%	-1.14M
Bioimpact capital	-	-	-1.11M

New Positions

Holder	Shares	% Assets	Change	Value
Panagora asset management	97.90K	0.00%	97.90K	$147.83K
Norges bank	71.53K	-	71.53K	$292.55K
Voleon capital management lp	27.16K	0.00%	27.16K	$41.01K
Optiver b.v.	44.00	-	44.00	$66.00
Allworth financial lp	42.00	-	42.00	$49.00

Sold Out

Holder	Change
Gamma investing	-2.00
True wealth design	-9.00
Advisor group	-10.00
Farther finance advisors	-10.00
Nelson, van denburg & campbell wealth management group	-11.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2025	95	-13.64%	52,043,002	0.86%	72	1.41%	41	-24.07%	28	-31.71%
Jun 30, 2025	115	-12.21%	55,620,773	31.52%	77	2.22%	58	-1.69%	42	-14.29%
Mar 31, 2025	134	-8.22%	58,450,755	-9.27%	81	0.99%	60	-34.07%	49	63.33%
Dec 31, 2024	139	0.72%	61,824,330	-12.88%	86	0.87%	85	19.72%	28	-26.32%
Sep 30, 2024	137	-4.86%	70,963,212	-7.43%	99	0.85%	71	-13.41%	38	-5.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Eventide Healthcare & Life Sciences I	2.83M	3.96%	-2.12M
Vanguard US Total Market Shares ETF	1.89M	2.64%	-
Eventide Gilead N	1.64M	2.30%	-1.94M
Vanguard Total Stock Mkt Idx Inv	1.55M	2.14%	-33.78K
Fidelity Growth Compy Commingled Pl O	1.16M	1.63%	-
FIAM Small Cap Core CIT Cl B	886.80K	1.25%	11.50K
Fidelity Growth Compy Commingled Pl S	881.46K	1.24%	-280.77K
FIAM Small Cap Core Composite	866.20K	1.22%	289.81K
Fidelity Small Cap Growth	734.93K	1.03%	-
PRIMECAP Odyssey Aggressive Growth	741.40K	1.03%	-172.00K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 30, 2025	Myers Scott Dunseth	-	Buy	$29.37K
Feb 06, 2025	Bruns Ingmar	Chief Medical Officer	Buy	$45.66K
Feb 03, 2025	Vultaggio Vincent	PAO and Interim PFO	Sell	$4.48K
Feb 03, 2025	Lackner Mark	Chief Scientific Officer	Sell	$24.59K
Feb 03, 2025	Paul Andrea	Chief Legal Officer	Sell	$22.64K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	-
2025 Q3	-	-
2025 Q2	1	-
2025 Q1	4	4
2024 Q4	-	1

ZNTL Ownership FAQ

Who Owns Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals shareholders are primarily institutional investors at 72.29%, followed by 13.52% insiders and 14.19% retail investors. The average institutional ownership in Zentalis Pharmaceuticals's industry, Biotech Stocks , is 45.22%, which Zentalis Pharmaceuticals exceeds.

Who owns the most shares of Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals’s largest shareholders are Matrix capital management company, lp (13.96M shares, 19.39%), Blackrock (4.82M shares, 6.80%), and Vanguard group (2.9M shares, 4.03%). Together, they hold 30.22% of Zentalis Pharmaceuticals’s total shares outstanding.

Does Blackrock own Zentalis Pharmaceuticals?

Yes, BlackRock owns 6.80% of Zentalis Pharmaceuticals, totaling 4.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.71M$. In the last quarter, BlackRock increased its holdings by 172.79K shares, a 3.72% change.

Who is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Mayo clinic is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 25.27% of its assets in 187.14K Zentalis Pharmaceuticals shares, valued at 765.42K$.

Who is the top mutual fund holder of Zentalis Pharmaceuticals shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Zentalis Pharmaceuticals shares, with 3.96% of its total shares outstanding invested in 2.83M Zentalis Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools